Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Travere Therapeutics, Inc. (TVTX : NSDQ)

• Company Description    Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. Travere Therapeutics Inc., formerly known as Retrophin Inc., is based in SAN DIEGO. Number of Employees: 385

• Price / Volume Information    Yesterday's Closing Price: $16.51 Daily Weekly Monthly 20 Day Moving Average: 1,294,566 shares Shares Outstanding: 88.81 (millions) Market Capitalization: $1,466.17 (millions) Beta: 0.72 52 Week High: $25.29 52 Week Low: $7.93 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 14.57% 8.81% 12 Week -6.35% -18.44% Year To Date -5.22% -11.48%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3611 VALLEY CENTRE DR SUITE 300 - SAN DIEGO,CA 92130 USA ph: 888-969-7879 fax: 302-645-1280 ir@travere.com https://travere.com

• General Corporate Information    Officers Eric Dube - Chief Executive Officer Gary Lyons - Chairman Christopher Cline - Chief Financial Officer Sandra Calvin - Senior Vice President and Chief Accounting Officer Roy D. Baynes - Director Peer Information Travere Therapeutics, Inc. (CORR.) Travere Therapeutics, Inc. (RSPI) Travere Therapeutics, Inc. (CGXP) Travere Therapeutics, Inc. (BGEN) Travere Therapeutics, Inc. (GTBP) Travere Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 89422G107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/07/25 Share - Related Items Shares Outstanding: 88.81 Most Recent Split Date: (:1) Beta: 0.72 Market Capitalization: $1,466.17 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.35 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.32 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/07/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 44.67 Price/Cash Flow: - Price / Sales: 5.36 EPS Growth vs. Year Ago Period: 73.30% vs. Previous Quarter: 35.62% Sales Growth vs. Year Ago Period: 97.54% vs. Previous Quarter: 9.29% ROE 06/30/25 - - 03/31/25 - -1,179.73 12/31/24 - -1,088.35 ROA 06/30/25 - - 03/31/25 - -41.10 12/31/24 - -55.44 Current Ratio 06/30/25 - - 03/31/25 - 2.05 12/31/24 - 2.08 Quick Ratio 06/30/25 - - 03/31/25 - 2.03 12/31/24 - 2.04 Operating Margin 06/30/25 - - 03/31/25 - -82.58 12/31/24 - -137.51 Net Margin 06/30/25 - - 03/31/25 - -82.88 12/31/24 - -137.90 Pre-Tax Margin 06/30/25 - - 03/31/25 - -82.60 12/31/24 - -137.46 Book Value 06/30/25 - - 03/31/25 - 0.37 12/31/24 - 0.76 Inventory Turnover 06/30/25 - - 03/31/25 - 1.94 12/31/24 - 1.34 Debt-to-Equity 06/30/25 - - 03/31/25 - 9.46 12/31/24 - 5.25 Debt-to-Capital 06/30/25 - - 03/31/25 - 90.44 12/31/24 - 84.01

Powered by Zacks Investment Research ©